unc-87 Antibody

What are the key structural and functional characteristics of UNC-87 proteins?

UNC-87 exists as two isoforms in C. elegans: UNC-87A (565 amino acids) and UNC-87B (374 amino acids). Both isoforms contain seven calponin-like (CLIK) repeats that function as actin-binding motifs. UNC-87A has an additional N-terminal extension of approximately 190 amino acids not present in UNC-87B . These proteins bind to both actin filaments and myosin, inhibiting actomyosin motility and inducing ATP-resistant actomyosin bundles . UNC-87 competes with actin-depolymerizing factor (ADF)/cofilin for binding to actin filaments, protecting them from severing . Despite their similar actin-stabilizing roles to tropomyosin, UNC-87 proteins appear to have distinct functions in sarcomere organization .

How are UNC-87 isoforms differentially expressed in C. elegans tissues?

The two UNC-87 isoforms are expressed via independent promoters in a tissue-specific manner. Promoter-reporter analysis has revealed distinct expression patterns, with UNC-87B being expressed in the myoepithelial sheath of the somatic gonad . Immunolocalization studies show that UNC-87B localizes along actin filaments and partially overlaps with regions where MYO-3 myosin is present . This tissue-specific expression pattern suggests specialized functions for each isoform in different cellular contexts.

What are recommended fixation protocols for UNC-87 immunostaining in C. elegans tissues?

For optimal UNC-87 detection in C. elegans tissues, a sequential fixation protocol is recommended. First, fix specimens in 4% paraformaldehyde in PBS for 10 minutes at room temperature, followed by post-fixation in cold (-20°C) methanol for 5 minutes. This dual fixation approach helps preserve both protein antigenicity and cellular architecture. After fixation, permeabilize tissues with 0.1% Triton X-100 in PBS for 10 minutes before proceeding with blocking and antibody incubation steps. This protocol has been successfully used to visualize UNC-87B localization along actin filaments in the myoepithelial sheath .

How should researchers design experiments to distinguish between UNC-87A and UNC-87B isoforms?

Distinguishing between UNC-87 isoforms requires careful experimental design due to their shared CLIK repeat regions. For antibody-based detection, target the unique N-terminal extension of UNC-87A for isoform-specific antibodies. When using commercial antibodies that recognize both isoforms, verify specificity through isoform-specific knockdown controls. Alternatively, employ genetic approaches using isoform-specific mutants or create transgenic lines expressing tagged versions of each isoform.

For biochemical assays, recombinant expression and purification of individual isoforms allows comparative analysis of their properties. Previous studies have shown that UNC-87A exhibits stronger actin-bundling activity than UNC-87B, and UNC-87A binds to actin and myosin more strongly than UNC-87B . When designing experiments, consider these quantitative differences in binding affinities and activities.

What controls are essential when using UNC-87 antibodies for immunolocalization studies?

For rigorous immunolocalization studies with UNC-87 antibodies, implement the following controls:

• Genetic validation: Include unc-87 mutant strains as negative controls. The alleles unc-87(e1216) and unc-87(e1459) are particularly useful, with e1216 showing mild defects and e1459 exhibiting severe phenotypes .

• Specificity controls: Perform pre-adsorption tests by incubating the primary antibody with purified recombinant UNC-87 protein before immunostaining.

• Isoform-specific controls: When studying a particular isoform, include tissues or cell types known to express only that isoform as internal positive controls.

• Co-localization validation: Perform double-labeling with established markers of actin filaments or myosin to confirm expected localization patterns, as UNC-87B has been shown to partially co-localize with both actin and MYO-3 myosin .

How can researchers quantitatively assess UNC-87 binding to actin and myosin in vitro?

Quantitative assessment of UNC-87 interactions with actin and myosin can be performed using several complementary approaches:

• Actin co-sedimentation assays: This method allows determination of binding affinities. Incubate varying concentrations of UNC-87 (1.0-20 μM) with F-actin (10 μM), ultracentrifuge, and analyze pellet and supernatant fractions by SDS-PAGE. Scatchard analysis has revealed that UNC-87 has two actin-binding sites with different affinities: a strong site (Ka = 6.5 ± 0.32 μM^-1) and a weak site (Ka = 0.31 ± 0.0067 μM^-1) .

• Myosin precipitation assays: Incubate UNC-87 with purified C. elegans myosin (Ce-myosin) at low ionic strength, centrifuge at low speed (15,000 × g, 30 min), and analyze supernatant and pellet fractions. Quantify precipitation at various UNC-87 concentrations to determine the dose-response relationship .

• Fluorescence microscopy of labeled proteins: Directly visualize interactions using fluorescently labeled actin filaments and assess bundle formation or protection against severing agents in the presence of UNC-87 .

How do UNC-87 isoforms differentially affect actomyosin contractility, and how can these effects be measured?

UNC-87 isoforms exhibit quantitatively different effects on actomyosin contractility. UNC-87A, with its N-terminal extension, binds more strongly to both actin and myosin than UNC-87B . Both isoforms inhibit actomyosin motility and induce ATP-resistant actomyosin bundles, but with different potencies.

To measure these differential effects, researchers can employ:

• In vitro motility assays: Measure actin filament gliding velocity on immobilized myosin in the presence of different concentrations of UNC-87A or UNC-87B. Both isoforms inhibit actomyosin motility, with UNC-87A showing stronger inhibition.

• Actin bundle morphology analysis: When combined with myosin, UNC-87A induces very large aggregates of actin bundles, whereas UNC-87B induces large but dispersed actin bundles . These differences can be visualized and quantified by fluorescence microscopy.

• In vivo contractility measurements: Analyze the myoepithelial sheath in the somatic gonad of C. elegans, where UNC-87B acts as a negative regulator of myosin-dependent contractility . Mutations in unc-87 enhance contraction of this nonstriated muscle, allowing quantitative assessment of contractility regulation in a physiological context.

What approaches can be used to investigate competitive binding between UNC-87 and other actin-binding proteins?

UNC-87 competes with actin-depolymerizing factor (ADF)/cofilin for binding to actin filaments. To investigate such competitive interactions, researchers can use:

• Sequential binding assays: Pre-incubate actin filaments with one protein (e.g., UNC-60B, the C. elegans ADF/cofilin) before adding UNC-87, and vice versa. When actin was preincubated with 10 μM UNC-87, UNC-60B binding to actin was decreased by 30-50% at 2.5 μM UNC-87 (actin:UNC-87 = 4:1) .

• Real-time visualization of competition: Immobilize fluorescently labeled actin filaments in a perfusion chamber, sequentially expose them to competing proteins, and monitor filament stability and morphology changes. UNC-87 has been shown to protect actin filaments from severing by UNC-60B using this approach .

• Functional competition assays: Assess how varying ratios of UNC-87 and competing proteins affect functional outcomes such as actin bundling or severing. At low UNC-60B concentrations, UNC-87's strong actin-binding site is effectively inhibited, while higher concentrations are needed to inhibit the weak binding site .

How can researchers analyze the regulatory roles of UNC-87 phosphorylation in actomyosin dynamics?

While the search results don't specifically address UNC-87 phosphorylation, this represents an important area for future investigation based on known regulatory mechanisms of other calponin-family proteins. To study potential phosphorylation-dependent regulation:

• Phosphorylation site prediction and mutagenesis: Use bioinformatics tools to predict potential phosphorylation sites, particularly in the unique N-terminal extension of UNC-87A. Generate phosphomimetic (S/T→D/E) and non-phosphorylatable (S/T→A) mutants for functional testing.

• In vitro phosphorylation assays: Identify kinases that might target UNC-87 based on consensus sequences, and perform in vitro kinase assays followed by mass spectrometry to map actual phosphorylation sites.

• Phosphorylation-specific antibodies: Develop antibodies that specifically recognize phosphorylated forms of UNC-87 for detection of in vivo phosphorylation states under different physiological conditions.

• Functional consequences: Compare the actin and myosin binding properties, as well as actomyosin regulatory activities, of phosphorylated versus non-phosphorylated UNC-87 using the quantitative methods described in section 2.3.

What are common issues when using UNC-87 antibodies in Western blots, and how can they be resolved?

When performing Western blots with UNC-87 antibodies, researchers might encounter several challenges:

• Poor discrimination between isoforms: UNC-87A (565 aa) and UNC-87B (374 aa) have similar electrophoretic mobilities to actin on SDS-PAGE . To improve resolution, use 7.5% acrylamide gels with extended run times and consider using gradient gels. Additionally, include appropriate positive controls of recombinant UNC-87A and UNC-87B proteins.

• Cross-reactivity with other calponin-family proteins: Due to the conserved CLIK repeats, validate antibody specificity using samples from unc-87 mutants and through pre-adsorption tests with recombinant proteins.

• Weak signal detection: Optimize protein extraction methods specifically for cytoskeletal proteins by using buffers containing 1% Triton X-100, 0.5% sodium deoxycholate, and protease inhibitors. For membrane transfer, consider using PVDF membranes and optimize transfer conditions for high-molecular-weight proteins.

How can immunoprecipitation protocols be optimized for studying UNC-87 protein interactions?

Optimizing immunoprecipitation (IP) protocols for UNC-87 requires consideration of its actin and myosin binding properties:

• Buffer composition: Use buffers that maintain native protein interactions while solubilizing UNC-87. Start with a base buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, and 1 mM DTT. For more stringent conditions, increase salt concentration to 300 mM NaCl.

• Pre-clearing strategy: Since UNC-87 binds strongly to actin filaments, include a pre-clearing step with protein A/G beads to reduce non-specific binding of cytoskeletal components.

• Antibody coupling: Covalently couple UNC-87 antibodies to beads using crosslinkers like dimethyl pimelimidate to prevent antibody contamination in the eluted samples.

• Two-step IP approach: For studying UNC-87 interactions with specific partners, consider a sequential IP approach - first immunoprecipitate UNC-87, then elute under mild conditions and perform a second IP with antibodies against potential interacting proteins.

What strategies can improve the specificity of immunofluorescence staining for UNC-87 in different C. elegans tissues?

To enhance immunofluorescence staining specificity for UNC-87 in C. elegans tissues:

• Optimized fixation: Different tissues may require modified fixation protocols. For dense tissues like body wall muscle, increase permeabilization time with Triton X-100 (0.5% for 15 minutes), while for more delicate structures like the somatic gonad, use gentler fixation (2% paraformaldehyde for 5 minutes).

• Antigen retrieval: In some cases, heat-mediated antigen retrieval (10 mM sodium citrate, pH 6.0, 95°C for 10 minutes) may enhance epitope accessibility, particularly for detecting UNC-87A.

• Signal amplification: For tissues with low UNC-87 expression, employ tyramide signal amplification (TSA) or use secondary antibodies conjugated to brighter fluorophores like Alexa Fluor 647.

• Blocking optimization: Include 5% BSA and 5% normal serum (matching the secondary antibody host species) in blocking buffer, and extend blocking time to 2 hours at room temperature to reduce background staining.

• Confocal imaging parameters: Use narrow bandpass filters and sequential scanning to minimize bleed-through when performing multi-color imaging, particularly when co-staining for actin and myosin with UNC-87.

How should researchers interpret discrepancies between in vitro and in vivo studies of UNC-87 function?

When analyzing potentially conflicting data between in vitro biochemical studies and in vivo genetic analyses of UNC-87 function:

• Consider isoform-specific effects: UNC-87A and UNC-87B have quantitatively different biochemical properties . Ensure that the same isoform is being studied in both contexts, or explicitly account for isoform differences.

• Examine concentration dependence: UNC-87's effects on actin and myosin are concentration-dependent. In vitro experiments typically use protein concentrations that may differ from physiological levels in specific tissues.

• Evaluate genetic compensation: In vivo studies using unc-87 mutants may be complicated by compensatory upregulation of other actin-stabilizing proteins. The actin-stabilizing role of UNC-87 is similar to that of tropomyosin, but they appear to have opposite roles in sarcomere organization , suggesting complex regulatory networks.

• Consider tissue-specific contexts: UNC-87's function may vary between different muscle types. While unc-87 mutations cause disorganized sarcomeric actin filaments in body wall muscle , genetic analysis shows that UNC-87B is a negative regulator of myosin-dependent contractility in the myoepithelial sheath of the somatic gonad .

What analytical methods are most appropriate for quantifying UNC-87's effects on actin dynamics and organization?

To quantitatively assess UNC-87's impact on actin dynamics and organization:

• Actin severing protection assays: Measure the protective effect of UNC-87 against UNC-60B (ADF/cofilin)-induced severing using time-lapse fluorescence microscopy. Calculate the percentage of intact filaments over time in the presence of different UNC-87 concentrations .

• Actin bundle analysis: Quantify bundle thickness, length, and density in the presence of UNC-87 alone or in combination with myosin. UNC-87A induces very large aggregates of actin bundles, whereas UNC-87B induces large but dispersed actin bundles when combined with C. elegans myosin .

• Competitive binding quantification: For analyzing competition between UNC-87 and other actin-binding proteins, use Scatchard analysis to determine changes in binding parameters (Ka values). UNC-87 has two actin-binding sites with different affinities (Ka = 6.5 ± 0.32 μM^-1 and Ka = 0.31 ± 0.0067 μM^-1) , which are differentially affected by competitors.

• In vivo sarcomere organization metrics: Develop quantitative measures of actin filament organization in muscle cells, such as sarcomere length variability, actin filament continuity, and co-localization coefficients with other sarcomeric proteins.

How can researchers effectively compare UNC-87 function across different model organisms?

While UNC-87 was initially characterized in C. elegans, related calponin-family proteins exist in other organisms. For comparative studies:

• Phylogenetic analysis: Conduct comprehensive sequence alignment and phylogenetic analysis of calponin-family proteins across species, focusing on conservation of the CLIK repeats and the N-terminal extension present in UNC-87A.

• Heterologous expression: Express C. elegans UNC-87 isoforms in other model systems (e.g., cultured mammalian cells, Drosophila) and assess their localization and effects on the actin cytoskeleton compared to endogenous calponin-family proteins.

• Cross-species rescue experiments: Test whether mammalian calponins can rescue phenotypes in unc-87 mutant C. elegans, and conversely, whether UNC-87 can substitute for calponin function in mammalian cell systems.

• Comparative biochemistry: Perform side-by-side biochemical assays comparing the actin and myosin binding properties of UNC-87 with calponins from other species under identical experimental conditions.